HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Geron Corporation (GERN) Investors With Losses to Contact its Attorneys: Application Deadline Approaching
SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses.
- SAN FRANCISCO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Geron Corporation (NASDAQ: GERN) who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses.
- Geron Corporation (GERN) Securities Class Action:
The complaint alleges that Geron misled investors about the results of a clinical study of Imetelstat, the Companys core drug intended to treat certain bone marrow cancers. - Were focused on investors losses and proving Geron misled investors by promoting Imetelstat while concealing material efficacy data, said Reed Kathrein, the Hagens Berman partner leading the investigation.
- If you purchased shares of Geron Corporation and suffered significant losses, click here to discuss your legal rights with Hagens Berman .